 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a clinical-stage biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2020, and highlighted recent corporate accomplishments. 